-
公开(公告)号：EP3458479B1
公开(公告)日：2020-11-04
申请号：EP17732657.6
申请日：2017-06-07
申请人： AbbVie Inc.
-
公开(公告)号：EP3458479A1
公开(公告)日：2019-03-27
申请号：EP17732657.6
申请日：2017-06-07
申请人： AbbVie Inc.
发明人： BENATUIL, Lorenzo , BRUNCKO, Milan , CHAO, Debra , IZERADJENE, Kamel , JUDD, Andrew, S. , PHILLIPS, Andrew, C. , SOUERS, Andrew, J. , THAKUR, Archana
摘要： The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：EP4364754A2
公开(公告)日：2024-05-08
申请号：EP24151653.3
申请日：2017-06-07
申请人： AbbVie Inc.
发明人： BENATUIL, Lorenzo , BRUNCKO, Milan , CHAO, Debra , IZERADJENE, Kamel , JUDD, Andrew S. , PHILLIPS, Andrew C. , SOUERS, Andrew J. , THAKUR, Archana
IPC分类号： A61K39/00
CPC分类号： A61K2039/50520130101 , C07K2317/2420130101 , C07K2317/3320130101 , C07K2317/5220130101 , C07K2317/9220130101 , C07K2319/5520130101 , A61K31/437 , A61K31/498 , A61K31/519 , A61K47/6877 , A61K47/6803 , A61K47/6849 , C07K16/2827 , C07K2317/3420130101 , C07K2317/5620130101 , C07K2317/56520130101 , C07K2317/7620130101 , A61P35/00 , A61P43/00
摘要： The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：EP3835322A3
公开(公告)日：2021-10-06
申请号：EP20198783.1
申请日：2017-06-07
申请人： AbbVie Inc.
发明人： BENATUIL, Lorenzo , BRUNCKO, Milan , CHAO, Debra , IZERADJENE, Kamel , JUDD, Andrew S. , PHILLIPS, Andrew C. , SOUERS, Andrew J. , THAKUR, Archana
摘要： The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：EP3469000A1
公开(公告)日：2019-04-17
申请号：EP17732658.4
申请日：2017-06-07
申请人： AbbVie Inc.
发明人： BENATUIL, Lorenzo , BRUNCKO, Milan , CHAO, Debra , IZERADJENE, Kamel , JUDD, Andrew, S. , PHILLIPS, Andrew, C. , SOUERS, Andrew, J. , THAKUR, Archana
IPC分类号： C07K16/28 , A61K47/68 , A61K31/337 , A61K39/00 , A61P35/00
-
公开(公告)号：EP2935331A1
公开(公告)日：2015-10-28
申请号：EP13821368.1
申请日：2013-12-23
申请人： AbbVie Inc.
发明人： ANDERSON, Mark , WANG, Jieyi , THAKUR, Archana , CHAO, Debra , HSIEH, Chung-Ming , ZHANG, Qian , REILLY, Edward, B. , DIGIAMMARINO, Enrico, L. , LONGENECKER, Kenton, L. , JUDGE, Russell, A. , EGAN, David, A. , HUTCHINS, Charles, W.
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
摘要翻译： 本发明包括PRLR结合蛋白。 具体而言，本发明涉及嵌合，CDR嫁接和人源化抗体的抗体。 优选的抗体对hPRLR具有高亲和力并在体外和体内中和hPRLR活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 例如，本发明的抗体或抗体部分可用于检测hPRLR和抑制hPRLR活性，例如在患有hPRLR活性有害的病症的人类受试者中。 本发明还包括抗PRLR抗体药物缀合物（ADC）。
-
公开(公告)号：EP3835322A2
公开(公告)日：2021-06-16
申请号：EP20198783.1
申请日：2017-06-07
申请人： AbbVie Inc.
发明人： BENATUIL, Lorenzo , BRUNCKO, Milan , CHAO, Debra , IZERADJENE, Kamel , JUDD, Andrew S. , PHILLIPS, Andrew C. , SOUERS, Andrew J. , THAKUR, Archana
摘要： The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：EP3468993A1
公开(公告)日：2019-04-17
申请号：EP17731045.5
申请日：2017-06-07
申请人： AbbVie Inc.
发明人： BENATUIL, Lorenzo , BRUNCKO, Milan , CHAO, Debra , DOHERTY, George , FREY, Robin R. , IZERADJENE, Kamel , JUDD, Andrew S. , PHILLIPS, Andrew C. , SONG, Xiaohong , SOUERS, Andrew J. , SULLIVAN, Gerard M. , TAO, Zhi-Fu , THAKUR, Archana
IPC分类号： C07K16/28 , A61K47/68 , A61K31/337 , A61K39/00 , A61P35/00
-
公开(公告)号：EP3363817A1
公开(公告)日：2018-08-22
申请号：EP18152359.8
申请日：2013-12-23
申请人： AbbVie Inc.
发明人： ANDERSON, Mark , WANG, Jieyi , THAKUR, Archana , CHAO, Debra , HSIEH, Chung-Ming , ZHANG, Qian , REILLY, Edward B. , DIGIAMMARINO, Enrico L. , LONGENECKER, Kenton L. , JUDGE, Russell A. , EGAN, David A. , HUTCHINS, Charles W.
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
公开(公告)号：EP2935331B1
公开(公告)日：2018-02-28
申请号：EP13821368.1
申请日：2013-12-23
申请人： AbbVie Inc.
发明人： ANDERSON, Mark , WANG, Jieyi , THAKUR, Archana , CHAO, Debra , HSIEH, Chung-Ming , ZHANG, Qian , REILLY, Edward, B. , DIGIAMMARINO, Enrico, L. , LONGENECKER, Kenton, L. , JUDGE, Russell, A. , EGAN, David, A. , HUTCHINS, Charles, W.
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.027 秒)
